Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 80

Sort by

Sort Order Select

Journal Articles

Complete responses in AL amyloidosis are unequal: the impact of free light chain mass spectrometry in AL amyloidosis

Blood (2024) 143 (13): 1259–1268.

https://doi.org/10.1182/blood.2023022399

Published: 2024

Includes: Supplemental data

Journal Articles

The Impact of Continuous Lenalidomide Maintenance Treatment on People Living with Multiple Myeloma - a Single-Centre Qualitative Service Evaluation

Caroline Buck, Francisco Castillo, Elena Bettio, Kwee Yong, Annabel Mcmillan, Lydia Sarah Hui Lee, Xenofon Papanikolaou, Ke Xu, Charalampia Kyriakou, Neil Rabin, Ashutosh D. Wechalekar, Rakesh Popat, Joanne Land, Orla McCourt, Helen Poole, Rachel Tarling, Abigail Fisher, Jonathan Sive

Blood (2023) 142 (Supplement 1): 6640.

https://doi.org/10.1182/blood-2023-184914

Published: 2023

Journal Articles

Hepatic Response and Progression Criteria in Light Chain Amyloidosis: A Multicenter Validation Study

Blood (2023) 142 (Supplement 1): 3411.

https://doi.org/10.1182/blood-2023-190226

Published: 2023

Journal Articles

High Responses Rates with Single Agent Belantamab Mafodotin in Relapsed Systemic AL Amyloidosis

Blood (2023) 142 (Supplement 1): 3408.

https://doi.org/10.1182/blood-2023-182042

Published: 2023

Journal Articles

Pooled Analysis of Safety from Birtamimab Phase 1-3 Studies in Patients with Light Chain (AL) Amyloidosis

Vaishali Sanchorawala, Ashutosh D Wechalekar, Efstathios Kastritis, Giovanni Palladini, Stefan Schönland, Raymond Comenzo, Anita D'Souza, Jack Khouri, Victor Jimenez-Zepeda, Katherine Ingrid Sprinz, Heather Hao, Wenying Huang, Laura Governale Aubrey, Morie A. Gertz

Blood (2023) 142 (Supplement 1): 3409.

https://doi.org/10.1182/blood-2023-174703

Published: 2023

Journal Articles

Limited Utility of Mayo 2012 Cardiac Staging System for Risk Stratification of Patients with Advanced Cardiac AL Amyloidosis - Analysis of a Uniformly Treated Cohort of 1275 Patients

Jahanzaib Khwaja, Sriram Ravichandran, Joshua Bomsztyk, Oliver Charles Cohen, Darren Foard, Ana Martinez - Naharro, Lucia Venneri, Marianna Fontana, Philip N Hawkins, Julian Gillmore, Helen J Lachmann, Shameem Mahmood, Carol Whelan, Ashutosh D. Wechalekar

Blood (2023) 142 (Supplement 1): 537.

https://doi.org/10.1182/blood-2023-178243

Published: 2023

Journal Articles

Real-World Treatment Patterns Following Update to National Comprehensive Cancer Network Guidelines for Light-Chain Amyloidosis: Results from a Us Administrative Claims Database

Jeffrey Thompson, Ashutosh D. Wechalekar

Blood (2023) 142 (Supplement 1): 7340.

https://doi.org/10.1182/blood-2023-190292

Published: 2023

Journal Articles

Infection Risk and Use of Prophylaxis with Anti-BCMA Bispecific T Cell Engagers and Belantamab Mafodotin for Patients with Relapsed and Refractory Multiple Myeloma

Rakesh Popat, Kathleen Cheok, Amrutha Sridhar, Conor Feely, Catriona Mactier, Annabel Mcmillan, Ashutosh D. Wechalekar, Neil Rabin, Jonathan Sive, Charalampia Kyriakou, Ke Xu, Xenofon Papanikolaou, Shameem Mahmood, Kwee Yong, Lydia Sarah Hui Lee

Blood (2023) 142 (Supplement 1): 4702.

https://doi.org/10.1182/blood-2023-182725

Published: 2023

Journal Articles

Efficacy and Safety of Belantamab Mafodotin Monotherapy in Patients with Relapsed or Refractory Light Chain Amyloidosis: A Phase 2 Study By the European Myeloma Network

Efstathios Kastritis, Giovanni Palladini, Meletios Athanasios Dimopoulos, Arnaud Jaccard, Giampaolo Merlini, Foteini Theodorakakou, Despina Fotiou, Monique C Minnema, Ashutosh D. Wechalekar, Elena Papachristou, Giorgos Psarros, Pieter Sonneveld, Stefan Schonland

Blood (2023) 142 (Supplement 1): 4779.

https://doi.org/10.1182/blood-2023-185861

Published: 2023

Journal Articles

Daratumumab in AL amyloidosis

Ashutosh D. Wechalekar, Vaishali Sanchorawala

Blood (2022) 140 (22): 2317–2322.

https://doi.org/10.1182/blood.2021014613

Published: 2022

Journal Articles

Efficacy and Safety of Belantamab Mafodotin Monotherapy in Patients with Relapsed or Refractory Light Chain Amyloidosis: A Phase 2 Study By the European Myeloma Network

Efstathios Kastritis, Giovanni Palladini, Meletios-Athanasios Dimopoulos, Arnaud Jaccard, Giampaolo Merlini, Foteini Theodorakakou, Despina Fotiou, Monique C. Minnema, Ashutosh D. Wechalekar, Sreeja Varghese, Kyriaki Manousou, Pieter Sonneveld, Stefan Schönland

Blood (2022) 140 (Supplement 1): 7294–7296.

https://doi.org/10.1182/blood-2022-169688

Published: 2022

Journal Articles

Survey of the Relevance of Quality of Life (QoL) Questionnaires (QoLQs) Currently Used to Evaluate Multiple Myeloma (MM) Patients' Qol in Real-World MM Patients and Healthcare Professionals (HCPs)

Sotirios Bristogiannis, Yadanar Lwin, Catherine SY Lecat, Joanne Sowter, Orla McCourt, Emma Dowling, Nuno Correia, Neil K Rabin, Ke Xu, Jonathan Sive, Xenofon Papanikolaou, Rakesh Popat, Lydia Lee, Annabel McMillan, Sosana Delimpasi, Ashutosh D. Wechalekar, Kwee Yong, Charalampia Kyriakou

Blood (2022) 140 (Supplement 1): 12506–12507.

https://doi.org/10.1182/blood-2022-167272

Published: 2022

Journal Articles

Low Toxicity and Disease Responses in Systemic AL-Amyloidosis Using an Yttrium-90 Labelled Anti-CD66 Monoclonal Antibody TLX66 As the Only Conditioning Prior to Autologous Stem Cell Transplantation

Mary Jessel, Kim H. Orchard, Ashutosh D. Wechalekar

Blood (2022) 140 (Supplement 1): 12711–12712.

https://doi.org/10.1182/blood-2022-169646

Published: 2022

Journal Articles

Type 1 Cryoglobulinaemia Associated with Waldenström Macroglobulinemia, IgM MGUS or Non-Hodgkin Lymphoma

Jahanzaib Khwaja, Simon Salter, Aisha S Patel, Robert Baker, Rajeev Gupta, Ali Rismani, Charalampia Kyriakou, Ashutosh D. Wechalekar, Josephine M.I. Vos, Shirley D'Sa

Blood (2022) 140 (Supplement 1): 3653–3654.

https://doi.org/10.1182/blood-2022-160438

Published: 2022

Journal Articles

Use of Matrix-Assisted Laser Desorption/Ionisation Time-of-Flight Mass Spectrometry (MALDI-TOF MS) Free Light Chain Assessment for the Diagnosis and Monitoring of Systemic Immunoglobulin Light Chain (AL) Amyloidosis

Blood (2022) 140 (Supplement 1): 2351–2353.

https://doi.org/10.1182/blood-2022-160018

Published: 2022

Journal Articles

Autologous Stem Cell Transplantation in AL-Amyloidosis Following Yttrium-90 Labelled Anti-CD66 Monoclonal Antibody As Sole Conditioning Is Associated with Low Toxicity and Demonstrable Disease Responses

Kim H. Orchard, Jon Langford, Paul Lloyd-Evans, Denise Phillips, Matthew Guy, Sofia Michopoulou, Gemma Lewis, Julian Williams, Clint Zvavamwe, Claire Hutchison, Jane Nunnick, Amanda Blackwell, Pei-San Chan, Caspar Wickham, Ann-Marie Quigley, Mark Cook, Graham Jackson, Philip N Hawkins, Ashutosh D. Wechalekar

Blood (2021) 138 (Supplement 1): 3819.

https://doi.org/10.1182/blood-2021-146300

Published: 2021

Journal Articles

Systemic Light Chain Amyloidosis across Europe: Key Outcomes from a Retrospective Study of 4500 Patients

Blood (2021) 138 (Supplement 1): 153.

https://doi.org/10.1182/blood-2021-152675

Published: 2021

Journal Articles

Subcutaneous Daratumumab with Bortezomib, Cyclophosphamide, and Dexamethasone in Patients with Newly Diagnosed Light Chain (AL) Amyloidosis: 18-Month Analysis of the Phase 3 ANDROMEDA Study

Blood (2021) 138 (Supplement 1): 159.

https://doi.org/10.1182/blood-2021-146820

Published: 2021

Journal Articles

Graded Renal Response Criteria for Light Chain (AL) Amyloidosis

Blood (2021) 138 (Supplement 1): 2721.

https://doi.org/10.1182/blood-2021-149594

Published: 2021

Journal Articles

Graded Cardiac Response Criteria for AL Amyloidosis: The Impact of Depth of Cardiac Response on Survival

Blood (2021) 138 (Supplement 1): 2720.

https://doi.org/10.1182/blood-2021-149222

Published: 2021

NARROW

Complete responses in AL amyloidosis are unequal: the impact of free light chain mass spectrometry in AL amyloidosis

The Impact of Continuous Lenalidomide Maintenance Treatment on People Living with Multiple Myeloma - a Single-Centre Qualitative Service Evaluation

Hepatic Response and Progression Criteria in Light Chain Amyloidosis: A Multicenter Validation Study

High Responses Rates with Single Agent Belantamab Mafodotin in Relapsed Systemic AL Amyloidosis

Pooled Analysis of Safety from Birtamimab Phase 1-3 Studies in Patients with Light Chain (AL) Amyloidosis

Limited Utility of Mayo 2012 Cardiac Staging System for Risk Stratification of Patients with Advanced Cardiac AL Amyloidosis - Analysis of a Uniformly Treated Cohort of 1275 Patients

Real-World Treatment Patterns Following Update to National Comprehensive Cancer Network Guidelines for Light-Chain Amyloidosis: Results from a Us Administrative Claims Database

Infection Risk and Use of Prophylaxis with Anti-BCMA Bispecific T Cell Engagers and Belantamab Mafodotin for Patients with Relapsed and Refractory Multiple Myeloma

Efficacy and Safety of Belantamab Mafodotin Monotherapy in Patients with Relapsed or Refractory Light Chain Amyloidosis: A Phase 2 Study By the European Myeloma Network

Daratumumab in AL amyloidosis

Efficacy and Safety of Belantamab Mafodotin Monotherapy in Patients with Relapsed or Refractory Light Chain Amyloidosis: A Phase 2 Study By the European Myeloma Network

Survey of the Relevance of Quality of Life (QoL) Questionnaires (QoLQs) Currently Used to Evaluate Multiple Myeloma (MM) Patients' Qol in Real-World MM Patients and Healthcare Professionals (HCPs)

Low Toxicity and Disease Responses in Systemic AL-Amyloidosis Using an Yttrium-90 Labelled Anti-CD66 Monoclonal Antibody TLX66 As the Only Conditioning Prior to Autologous Stem Cell Transplantation

Type 1 Cryoglobulinaemia Associated with Waldenström Macroglobulinemia, IgM MGUS or Non-Hodgkin Lymphoma

Use of Matrix-Assisted Laser Desorption/Ionisation Time-of-Flight Mass Spectrometry (MALDI-TOF MS) Free Light Chain Assessment for the Diagnosis and Monitoring of Systemic Immunoglobulin Light Chain (AL) Amyloidosis

Autologous Stem Cell Transplantation in AL-Amyloidosis Following Yttrium-90 Labelled Anti-CD66 Monoclonal Antibody As Sole Conditioning Is Associated with Low Toxicity and Demonstrable Disease Responses

Systemic Light Chain Amyloidosis across Europe: Key Outcomes from a Retrospective Study of 4500 Patients

Subcutaneous Daratumumab with Bortezomib, Cyclophosphamide, and Dexamethasone in Patients with Newly Diagnosed Light Chain (AL) Amyloidosis: 18-Month Analysis of the Phase 3 ANDROMEDA Study

Graded Renal Response Criteria for Light Chain (AL) Amyloidosis

Graded Cardiac Response Criteria for AL Amyloidosis: The Impact of Depth of Cardiac Response on Survival

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only